(2RS,3S)-2-hydroxy-3-[N-(2-methyl-2-propyloxycarbonyl)amino]heptanoic acid | 209398-27-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (2RS,3S)-2-hydroxy-3-[N-(2-methyl-2-propyloxycarbonyl)amino]heptanoic acid
• 英文别名: (3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxyheptanoic acid；(3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]heptanoic acid
• CAS: 209398-27-6
• 化学式: C₁₂H₂₃NO₅
• 分子量: 261.318
• InChiKey: KRQDJBAPRVIAFS-IENPIDJESA-N

物化性质

• 沸点：
  425.8±35.0 °C(Predicted)
• 密度：
  1.127±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  18
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  95.9
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (2RS,3S)-2-hydroxy-3-[N-(2-methyl-2-propyloxycarbonyl)amino]heptanoic acid 在 碳酸氢钠 2,2,6,6-tetramethyl-piperidine-N-oxyl 、 sodium hypochlorite 、 1-羟基苯并三唑 、 1-(3-二甲基氨基丙基)-3-乙基碳二亚胺 、 N,N-二异丙基乙胺 、 potassium bromide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 tert-butyl(S)-1,2-dioxo-1-((R)-1-phenylethylamino)heptan-3-ylcarbamate
  参考文献：
  名称：

  Design of small molecule ketoamide-based inhibitors of cathepsin K

  摘要：

  A novel series of ketoamide-based inhibitors of cathepsin K has been identified. Modifications to p(2) and p(3) elements were crucial to enhancing inhibitory activity. Although not optimized, a selected inhibitor was effective in attenuating type 1 collagen hydrolysis in a surrogate assay of bone resorption. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.029
• 作为产物：
  描述：

  [(S)-1-(Cyano-hydroxy-methyl)-pentyl]-carbamic acid tert-butyl ester 在 盐酸 、 sodium hydroxide 、 二碳酸二叔丁酯 作用下， 以 四氢呋喃 为溶剂， 生成 (2RS,3S)-2-hydroxy-3-[N-(2-methyl-2-propyloxycarbonyl)amino]heptanoic acid
  参考文献：
  名称：

  Design of small molecule ketoamide-based inhibitors of cathepsin K

  摘要：

  A novel series of ketoamide-based inhibitors of cathepsin K has been identified. Modifications to p(2) and p(3) elements were crucial to enhancing inhibitory activity. Although not optimized, a selected inhibitor was effective in attenuating type 1 collagen hydrolysis in a surrogate assay of bone resorption. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.029

文献信息

• Potent peptide α-Ketohydroxamate inhibitors of recombinant human calpain I
  作者：Kurt A Josef、Frederick W Kauer、Ron Bihovsky

  DOI：10.1016/s0960-894x(01)00526-1

  日期：2001.10

  A series of potent dipeptide and tripeptide alpha-ketohydroxamic esters was prepared as inhibitors of recombinant human calpain I. Compound 3c, a Cbz-Leu-Phe hydroxamate, displayed the greatest potency against calpain I (IC(50)=6nM), while two compounds, 3l and 3m, both possessing the Cbz-Leu-Leu-Phe sequence, were the most potent (IC(50)=0.2 microM) in a MOLT-4 cell assay.

  制备了一系列有效的二肽和三肽α-酮异羟肟酸酯作为重组人钙蛋白酶I的抑制剂。化合物3c，一种Cbz-Leu-Phe异羟肟酸酯，对钙蛋白酶I具有最大的效力（IC（50）= 6nM），而两种在MOLT-4细胞分析中，具有Cbz-Leu-Leu-Phe序列的3l和3m化合物是最有效的（IC（50）= 0.2 microM）。
• Cyclic amide derivatives
  申请人：Fujirebio Kabushiki Kaisha

  公开号：US06117870A1

  公开（公告）日：2000-09-12

  A cyclic amide derivative of formula (I): ##STR1## wherein R.sup.1 represents a substituted alkyl group, a substituted alkenyl group, a substituted amino group, a substituted alkoxyl group, a substituted alkylthio group, a substituted carbamoyl group, a substituted sulfonamide group or a substituted amide group; the ring A represents a saturated cyclic alkyl group with 5 to 7 carbon atoms or a hetero-atom-containing saturated heterocyclic group with 3 to 6 carbon atoms; R.sup.2 represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group; R.sup.3 represents a hydrogen atom, a group represented by the general formula R.sup.4 O-- or a group represented by the general formula R.sup.5 (R.sup.6)N-- wherein R.sup.4 represents hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group; R.sup.5 and R.sup.6 may be the same or different and each represents a hydrogen atom, a substituted or unsubstituted alkyl group, a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted heterocyclic group. The cyclic amide derivative of formula (I) have a strong and selective inhibitory action of a cathepsin K and a clinical efficacy when administered orally.

  公式（I）的环酰胺衍生物：##STR1## 其中，R1代表取代的烷基，取代的烯基，取代的氨基，取代的烷氧基，取代的烷硫基，取代的氨基甲酰基，取代的磺酰胺基或取代的酰胺基；环A代表具有5至7个碳原子的饱和环烷基或具有3至6个碳原子的含杂原子的饱和杂环基；R2代表氢原子，取代或未取代的烷基，取代或未取代的芳香族烃基或取代或未取代的杂环基；R3代表氢原子，由一般式R4O-表示的基团或由一般式R5（R6）N-表示的基团，其中，R4代表氢原子，取代或未取代的烷基，取代或未取代的芳香族烃基或取代或未取代的杂环基；R5和R6可以相同也可以不同，且每个代表氢原子，取代或未取代的烷基，取代或未取代的芳香族烃基或取代或未取代的杂环基。公式（I）的环酰胺衍生物具有强大和选择性的卡他普辛K抑制作用，并在口服给药时具有临床疗效。
• Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
  申请人：Barrett Gene David

  公开号：US20050245596A1

  公开（公告）日：2005-11-03

  Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.

  本文描述了公式(I)的杂环取代酮酰胺衍生物，其中替代基A、D、A和R如权利要求中所定义，这些衍生物可用作卡特普西林K抑制剂。所述发明还包括制备这种杂环取代酮酰胺衍生物的方法，以及使用它们制造治疗与骨吸收和形成失衡有关的疾病（例如骨质疏松症），最终可能导致骨折的药物的方法。
• Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss
  申请人：SmithKline Beecham Corporation

  公开号：US07402606B2

  公开（公告）日：2008-07-22

  Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.

  本文描述了公式（I）的杂环取代酮酰胺衍生物，其中替代物A、D、A和R如权利要求中所定义，这些衍生物对于作为卡他普星K抑制剂是有用的。所述发明还包括制备这种杂环取代酮酰胺衍生物的方法，以及使用它们制造治疗与骨吸收和形成不平衡相关的疾病，包括骨质疏松症，最终可能导致骨折的药物的方法。
• P2–P3 conformationally constrained ketoamide-based inhibitors of cathepsin K
  作者：David G. Barrett、Virginia M. Boncek、John G. Catalano、David N. Deaton、Anne M. Hassell、Cynthia H. Jurgensen、Stacey T. Long、Robert B. McFadyen、Aaron B. Miller、Larry R. Miller、J. Alan Payne、John A. Ray、Vicente Samano、Lisa M. Shewchuk、Francis X. Tavares、Kevin J. Wells-Knecht、Derril H. Willard、Lois L. Wright、Hui-Qiang Q. Zhou

  DOI：10.1016/j.bmcl.2005.05.062

  日期：2005.8

  An orally bioavailable series of ketoamide-based cathepsin K inhibitors with good pharmacokinetic properties has been identified. Starting from a potent inhibitor endowed with poor drug properties, conformational constraint of the P(2)-P(3) linker and modifications to P(1') elements led to an enhancement in potency, solubility, clearance, and bioavailability. These optimized inhibitors attenuated bone resorption in a rat TPTX hypocalcemic bone resorption model.